Philipp Hellmich
philipp.hellmich@hartmann.info
+49 173 4794858
Company already complies with all requirements of the EU Medical Device Regulation (MDR):
Heidenheim, February 9, 2023. PAUL HARTMANN AG has already today completely transferred all product groups to the new EU Medical Device Regulation. The planned deadline extension by the EU is thus not relevant for the company. HARTMANN is further strengthening its supply abilities: the company's customers can rely on their products, being safe and available in the long term including new and significantly changed products.
HARTMANN already started implementing the MDR in 2017 and worked together with TÜV SÜD as the Notified Body at an early stage. "For us, a speedy implementation of the MDR was crucial. After all, our customers should be able to focus on their patients, not on regulatory requirements. We take care of that for them," says Stefan Fischer, Global Head of Regulatory Affairs at HARTMANN GROUP.
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.